Akero Therapeutics Inc. (AKRO)

The total asset value of Akero Therapeutics Inc. (AKRO) stood at $ 365 Mln as on 31-Mar-23

The share price of Akero Therapeutics Inc. (AKRO) is $19.06 (NASDAQ) as of 06-Dec-2023 16:00 EST. Akero Therapeutics Inc. (AKRO) has given a return of -12.56% in the last 3 years.

Akero Therapeutics Inc. (AKRO) has a market capitalisation of $ 2,585 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Akero Therapeutics Inc. (AKRO) is 6.03 times as on 02-Jun-2023, a 1.37% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Akero Therapeutics Inc. (AKRO) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Akero Therapeutics Inc. (AKRO) and enter the required number of quantities and click on buy to purchase the shares of Akero Therapeutics Inc. (AKRO).

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

The CEO & director of Dr. Andrew Cheng M.D., Ph.D.. is Akero Therapeutics Inc. (AKRO), and CFO & Sr. VP is Dr. Jonathan M. Young J.D., Ph.D..

The promoters of Akero Therapeutics Inc. (AKRO) have pledged 0% of the total equity as on Apr-23.

Some of the close peers are:

No, TTM profit after tax of Akero Therapeutics Inc. (AKRO) was $-112 Mln.